Institute of Bioorganic Chemistry

http://iboch.bas-net.by/  

Medicinal product - antitumor drug Decitabine and technology for producing the substance

COUNTRY OF ORIGIN

Belarus

IDENTIFIER

BO6574

PUBLISHED

2023-03-25

LAST UPDATE

2023-03-25

DEADLINE

Linked profile in other language
Responsible
Aleksej Yantsevich
+375 17 357 8761
info@iboch.by
Summary
The Institute of Bioorganic Chemistry offers consumers a medicinal product - the antitumor drug Decitabine on the basis of a manufacturing agreement, a technology for obtaining a substance on the basis of a license agreement, and is looking for partners to conclude a distribution services agreement.
Description
Pharmaceutical substance Decitabine, lyophilized powder for solution for infusion, 50 mg in packs No. 1 and No. 5. An original technology has been developed for the production of the pharmaceutical substance and the drug "Decitabine" - an antitumor drug for the treatment of myelodysplastic syndrome (MDS) of all types.
Advantages and Innovations
Import-substituting technology
Stage of development
Already on the market
Comments regarding stage of development
A pilot production technology for the production of the pharmaceutical substance and the medicinal product "Decitabine" has been developed; the pharmaceutical substance Decitabine (FSP RB 1941-14; RU No. 14/05/2231 dated 05/28/2014) and a drug based on it (FSP RB 2147-15; RU No. 15/09/2444 dated 09/01/2015) were registered.
Funding source
State budged
Internal
IPR status
Exclusive rights
Secret know-how
Sector group
BioChemTech
Healthcare

Client information

Type
R&D institution
Year established
1974
NACE keywords
C.21.10 - Manufacture of basic pharmaceutical products
C.21.20 - Manufacture of pharmaceutical preparations
C.20.59 - Manufacture of other chemical products n.e.c.
M.72.19 - Other research and experimental development on natural sciences and engineering
M.74.90 - Other professional, scientific and technical activities n.e.c.
Turnover (in EUR)
10-20M
Already engaged in transnational cooperation
Yes
Additional comments
The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For pilot production of the developed products (hemosorbents, preparations of recombinant enzymes, immunochemical reagents, oxyphitosterols, etc.), 5 experimental production sites have been created at the institute.

The results of fundamental and applied research on methods and means of protecting plants from diseases, insects, weeds, and other unfavorable environmental factors that are safe for humans and the biosphere as a whole were the basis for the development of methods for obtaining new plant growth stimulators, pheromone compositions (pheromones of the codling moth LP -U and mill moth), active ingredients of pesticides (analogs of the herbicide Grasp and insecticide Confidor), formulations of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of patents maintained in force, laboratory technological and experimental industrial regulations, technical specifications, and trademarks. Licensing agreements are in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents, and pesticides to manufacturers.
Languages spoken
English
Russian

Information about partnership

Type of partnership considered
Distribution services agreement
License agreement
Manufacturing agreement
Type and role of partner sought
Consumers interested in purchasing the anticancer drug Decitabine under a manufacturing agreement.

Distributors interested in purchasing the anticancer drug Decitabine under a distribution services agreement.

Partners interested in acquiring technology for obtaining the substance of the anticancer drug Decitabine under a license agreement.
Type and size of partner sought
> 500 MNE
> 500
251-500
SME 51-250
SME 11-50
SME <= 10
R&D Institution
University

Attachments

Views: 689
Statistics since 25.03.2023 21:12:47